Search Results for "edoxaban"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for edoxaban. Results 11 to 12 of 12 total matches.
See also: Savaysa
Balfaxar: Another Four-Factor PCC for Warfarin Reversal
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
) and it probably can be used
(not FDA-approved) for edoxaban (Savyasa) as well.
When andexanet alfa ...
Balfaxar (Octapharma), a human plasma-derived
four-factor prothrombin complex concentrate (PCC),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent surgical/invasive procedure. It is the second
four-factor PCC to become available in the US;
Kcentra, which has been available since 2013, is
approved for the same indication and for urgent
reversal of warfarin anticoagulation in adults with
acute major bleeding. Balfaxar is marketed in Canada
and Europe as Octaplex.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):31-2 doi:10.58347/tml.2024.1696d | Show Introduction Hide Introduction
Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018 (Issue 1537)
after hip replacement. The direct factor Xa
inhibitor edoxaban (Savaysa) is not approved ...
The FDA has approved betrixaban (Bevyxxa –
Portola), a once-daily, oral, direct factor Xa inhibitor,
for prophylaxis of venous thromboembolism (VTE)
in adults hospitalized for an acute medical illness
who have moderately or severely restricted mobility
and other risk factors for VTE. Betrixaban is the
first oral anticoagulant to be approved in the US for
this indication.